

REMARKS

The pending claims have been rejected as being indefinite and as not satisfying the written description requirement. This rejection is respectfully traversed in light of the amendments and arguments herein.

The Amended Claims Are Definite

Claim 1 has been amended to recite that it is the lysyl oxidase pro-peptide **portion** of the polypeptide in the claimed composition that is therapeutically active in inhibiting cell growth or proliferation. Thus, Applicants submit that the amended claims are definite and that this rejection has been overcome.

The Amended Claims Satisfy the Written Description Requirement

Claim 1 has been amended to recite that the lysyl oxidase pro-peptide **portion** of the polypeptide in the claimed composition is that of human, mouse or rat. Additional amendments have also been made in claims 4 and 5. Thus, Applicants submit that the amended claims satisfy the written description requirement and that this rejection also has been overcome.

Applicants submit that all claims are in condition for allowance and such action is respectfully requested.

Application No. 10/585,651
Filed: July 07, 2006
TC Art Unit: 1652
Confirmation No.: 5481

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter that would expedite allowance of the present application.

Respectfully submitted,

Philip C. Trackman et al.

Dated: May 24, 2010

By: Holliday C. Heine/
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEOVICI LLP
Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

HCH/nja

389263.1